Titlebook: DNA Topoisomerases in Cancer Therapy; Present and Future Toshiwo Andoh Book 2003 Springer Science+Business Media New York 2003 DNA.biology.

Ejaculate

Degradation of topoisomerase cleavable complexes,NA transcription, chromosomal condensation/ decondensation and chromosome segregation (Castano .., 1996; Champoux and Dulbecco, 1972; Liu, 1989; Wang, 1985; Wang, 1996; Zhang .., 2000). So far, six human DNA topoisomerases, hTOPl, hTOP2a, hTOP2β, hTOP3a, hTOP3β and mitochondrial hTOPl, have been ide

Inflammation

Yeast as a model system in the analysis of DNA topoisomerase I poisons,id .., 1998; Champoux, 2001; Wang, 2002). The nuclear enzyme, encoded by the . gene, is highly conserved in terms of reaction mechanism, structure and sensitivity to anticancer agents such as the camptothecins (Redinbo .l., 1999; Fiorani and Bjornsti, 2000; Li and Liu, 2001). As with other DNA topoi

攀登

Understanding the action of drugs targeting TOP2: ,,). The enzyme has been termed a simple molecular machine that orchestrates DNA topology by its ability to pass a double stranded DNA through a transient DNA double strand break (Wang 1998). The complexity of the reactions carried out by topoisomerase II, along with its importance in DNA metabolism h

Processes

Cellular resistance to DNA Topoisomerase I-targeting drugs, replication, recombination and transcription. The enzyme catalyzes a concerted chain of reactions, .. DNA single-strand break, concomitant covalent binding of the protein to 3’-end of the DNA break, passage of the other strand through the gap and rejoining of the DNA (Wang, 2002).

提名

Development of new topoisomerase I-targeting compounds as candidate anticancer drugs,ecin was found clinically active but was discontinued in the 70’s because of severe side effects and lack of understanding of the drug’s mechanism of action. The finding in 1985 that top1 was the target of camptothecin generated great interest to find water-soluble, more efficacious and less toxic a

咯咯笑

Development of new topoisomerase II-targeting compounds as candidate anticancer drugs,e dynamics. Two types of enzymes, type I and II, are validated targets of a number of efficacious anticancer drugs. Doxorubicin, etoposide, amsacrine and mitoxantrone are among others are frequently prescribed drugs targeting type II enzyme, topo II. There have been enormous efforts in search for ne

追踪

SEVER

ML Models: Food Security and Climate Changeere trying to take advantage of a report five years earlier that the enzyme . DNA polymerase I could incorporate a ribonucleotide into its product under certain conditions. This misincorporation of a ribo- rather the normal deoxyribonucleotide, I reasoned, might be exploited to generate a set of fou

健壮

Restenosis

Seungcheol Austin Lee,Yuhua (Jake) Liangssential role in survival of cells. Compounds are classified roughly into two, those progressed into the stage of clinical trial and those in preclinical experiments. Among the latter we included topo inhibitors which are being developed by multi-institutional collaboration in Japan.